3,918 reports of this reaction
1.4% of all CYCLOPHOSPHAMIDE FOR INJECTION reports
#20 most reported adverse reaction
MYELOSUPPRESSION is the #20 most commonly reported adverse reaction for CYCLOPHOSPHAMIDE FOR INJECTION, manufactured by Hainan Poly Pharm. Co., Ltd.. There are 3,918 FDA adverse event reports linking CYCLOPHOSPHAMIDE FOR INJECTION to MYELOSUPPRESSION. This represents approximately 1.4% of all 284,203 adverse event reports for this drug.
Patients taking CYCLOPHOSPHAMIDE FOR INJECTION who experience myelosuppression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MYELOSUPPRESSION is a less commonly reported adverse event for CYCLOPHOSPHAMIDE FOR INJECTION, but still significant enough to appear in the safety profile.
In addition to myelosuppression, the following adverse reactions have been reported for CYCLOPHOSPHAMIDE FOR INJECTION:
The following drugs have also been linked to myelosuppression in FDA adverse event reports:
MYELOSUPPRESSION has been reported as an adverse event in 3,918 FDA reports for CYCLOPHOSPHAMIDE FOR INJECTION. This does not prove causation, but indicates an association observed in post-market surveillance data.
MYELOSUPPRESSION accounts for approximately 1.4% of all adverse event reports for CYCLOPHOSPHAMIDE FOR INJECTION, making it a notable side effect.
If you experience myelosuppression while taking CYCLOPHOSPHAMIDE FOR INJECTION, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.